

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/021457-2022>

Planning

Managed Service for the Bacterial Screening of Platelets

NHS Blood and Transplant

F01: Prior information notice

Prior information only

Notice identifier: 2022/S 000-021457

Procurement identifier (OCID): ocds-h6vhtk-03590d

Published 4 August 2022, 4:03pm

Section I: Contracting authority

I.1) Name and addresses

NHS Blood and Transplant

500 North Bristol Park

Bristol

BS34 7QH

Contact

Jo Murphy

Email

jo.murphy@nhsbt.nhs.uk

Telephone

+44 1179212718

Country

United Kingdom

NUTS code

UKK11 - Bristol, City of

National registration number

NHS Blood and Transplant

Internet address(es)

Main address

<https://www.nhsbt.nhs.uk/>

Buyer's address

<https://www.nhsbt.nhs.uk/>

I.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Managed Service for the Bacterial Screening of Platelets

II.1.2) Main CPV code

- 85111810 - Blood analysis services

II.1.3) Type of contract

Services

II.1.4) Short description

This Prior Information Notice (PIN) follows 2021/S 000-013561 released on the 16th June 2021 and all information herein supersedes that of 2021/S 000-013561.

This Prior Information Notice (PIN) is separate to any tender opportunity and not related in any form whatsoever to any subsequent activity that NHSBT may wish to pursue. The purpose of this PIN is to consult the market to improve NHSBT's knowledge on the status of manufacturer(s) or economic operator(s) that can supply a commercially available automated, high-throughput automated bacterial screening system which can detect bacterial contamination in platelet components.

NHSBT needs to gauge market interest in a new provision of this service. It is the intention of NHSBT to further consult and engage with only those manufacturer(s) and economic operator(s) who meet the outline requirements.

II.1.5) Estimated total value

Value excluding VAT: £31,200,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 33696200 - Blood-testing reagents

- 38434520 - Blood analysers
- 48921000 - Automation system
- 71632000 - Technical testing services
- 85111810 - Blood analysis services
- 71600000 - Technical testing, analysis and consultancy services
- 85146000 - Services provided by blood banks
- 71900000 - Laboratory services
- 33698100 - Microbiological cultures

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. All invitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked. GB will continue to recognise CE marking under the IVDD or IVDR until 30 June 2023 and from 1 July 2023 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system (PULSE) without the need for changes to PULSE.

NHSBT are looking for a fully integrated, high throughput, automated bacterial screening system which can detect bacterial contamination in platelet components. The system will be used in Filton (Bristol), Manchester and Colindale (London) where approximately 270,000 adult therapeutic doses of platelets are manufactured each year. NHSBT are seeking to engage with suppliers who can provide this. The system must be CE/UKCA marked. Additional requirements to be included with the managed service contract include:

- continuous calibrated temperature monitoring
- ability to integrate with NHSBT information management system
- alerting software (for positive results, hardware errors, temperature excursions)
- consumables (including, but not limited to, sterile sampling connecting devices)

All test protocols must be in accordance with the Guidelines for the Blood Transfusion service in the United Kingdom (<https://www.transfusionguidelines.org/red-book>) and the Good Practice Guidelines for Blood Establishments that are Required to Comply with Directive 2005/62/EC. These are published in the 20th edition of the Guide to the preparation, use and quality assurance of blood components.

It is NHSBTs' intention to engage with the market to gather detailed information about the market capabilities. The format for this will be communicated to those that respond to this PIN. Virtual Supplier Engagement days are likely to be a Webinar followed by individual supplier presentation days. Expressions of interest should be e-mailed to jo.murphy@nhsbt.nhs.uk by no later than 12:00 hours on 25th August 2022.

II.3) Estimated date of publication of contract notice

1 November 2022

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes